Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Antiviral Res. 2014 Oct 31;113:49–61. doi: 10.1016/j.antiviral.2014.10.011

Figure 6. Determination of convallatoxin antiviral activity using a clinical infection model.

Figure 6

(A). ARPE-19 epithelial cells were infected with the clinical CMV strain TB40/EFLAG-YFP (MOI:20). Fluorescence signal was measured using an Acumen eX3 cytometer. The number of YFP+ cells/well was plotted over the course of infection (up to 7dpi.) (B) ARPE-19 epithelial cells treated with DMSO and increasing amounts of convallatoxin (0-10 nM) were infected with TB40/EFLAG-YFP (MOI:20) and analyzed for YFP+ cells. The % infection (left axis, black lines, filled circles) was determined based on the YFP+ cells using DMSO-treated cells as 100% infection. The intranuclear cell staining using NucGreen fluorescent cell dye (GFP + cells) was utilized to determine cell viability (right axis, gray lines and gray circles) with DMSO treated cells as 100% cell viability. Error bars represent standard error of the mean.